Selank was developed in Russia as an anxiolytic peptide and has published human studies in generalised anxiety, mostly intranasal. As with Epithalon, the literature is regionally concentrated and lightly replicated elsewhere.
Read this first
Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.
Compound at a glance
Class
Tuftsin analogue heptapeptide
Reported half-life
Short systemically; intranasal studies report rapid CNS appearance
Routes used in the literature
Intranasal in the human literature; intraperitoneal in animal work
Also written as
—
What the published studies reported
Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.
Russian anxiety studies (intranasal)
Reported quantity
Around 250–350 µg/kg per day, delivered as a 0.15% solution
Frequency
Two to three divided administrations daily
Study duration
14 days in the published trial arms
Drops per nostril rather than milligrams is how the source protocols express this.
Rodent anxiolytic models
Reported quantity
0.1–0.3 mg/kg intraperitoneally
Frequency
Once daily
Study duration
Single administration to 14 days
Elevated plus-maze and open-field behaviour are the standard readouts.
Dosage chart
These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.
Selank · 10 mg Vial
This Selank dosage chart explains how a 10 mg vial can be calculated for intranasal research with a verified 0.10 mL metered actuator. Published human Selank studies primarily used intranasal drops or measured intranasal solution. A measured 5 mL final volume provides 200 mcg per spray, while a measured 10 mL final volume provides 100 mcg per spray.
Primary human research route
Intranasal drops or measured intranasal solution.
5 mL final volume
2 mg/mL, 200 mcg per verified 0.10 mL spray, and 50 nominal sprays.
10 mL final volume
1 mg/mL, 100 mcg per verified 0.10 mL spray, and 100 nominal sprays.
Device check
Confirm the pump output and follow its priming instructions before using the calculation.
Research context
Human studies used different amounts, durations, and manufactured drop formulations.
The same arithmetic for every vial size Selank is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.
Selank · 3 ml bacteriostatic water
Vial size
Concentration
Per 1 unit
5 mg
1.67 mg/ml
17 mcg
11 mg
3.67 mg/ml
37 mcg
No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.
Reconstitution maths
A 10 mg vial in 2 mL of bacteriostatic water gives 5 mg/mL, equivalent to a 0.5% solution before dilution.
Intranasal delivery efficiency varies enormously with formulation and technique.
Peer review standards in the source literature are not equivalent to Western registered trials.
BDNF and GABA-related mechanisms are proposed rather than established.
Sources and citations
These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.
[1]
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Semenova TP, Kozlovskaya MM, et al. · Zh Nevrol Psikhiatr Im S S Korsakova · 2008 · PMID 18454096
62 patients with generalized anxiety disorder and neurasthenia received Selank (dosing per Russian regulatory protocol, intranasal) compared against the benzodiazepine medazepam to assess anxiolytic efficacy.
Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.
Share
Independent publication — we sell nothing. Supplier disclosure
Peptide Intel Hub is an independent educational publication. We are not affiliated with, owned by, or the same company as Regena Peptides and Regena.app (regena-peptides.com / regena.app). We do not sell, supply, ship or take payment for any compound. Because readers regularly ask where compounds discussed in published studies can be sourced for laboratory work, we list Regena Peptides and Regena.app as suppliers we have verified and trust — every batch is released with a lot-matched third-party certificate of analysis (HPLC purity and mass-spectrometry identity). Outbound links are marked nofollow/sponsored and are provided to help readers, not to sell.